Portfolio Manager Factsheet
The start of 2017 was a relatively healthy one for global healthcare stocks. While the political environment in the United States remains front page news, rhetoric on putative legislation on drug pricing may have taken a back seat in the month. Bristol-Myers Squibb was lower as it announced that their accelerated filing strategy for their combination therapy in the treatment of frontline lung cancer, Opdivo + Yervoy, would not go forward as planned.
Worldwide Healthcare Trust PLC conducts its affairs so that its shares can be recommended by independent financial advisers (IFAs) to retail private investors. The shares are excluded from the Financial Conduct Authority's (FCA's) restrictions which apply to non-mainstream investment products because they are shares in a UK-listed investment trust.